262 related articles for article (PubMed ID: 12384979)
1. K vitamins, PTP antagonism, and cell growth arrest.
Carr BI; Wang Z; Kar S
J Cell Physiol; 2002 Dec; 193(3):263-74. PubMed ID: 12384979
[TBL] [Abstract][Full Text] [Related]
2. Involvement of hepatocyte epidermal growth factor receptor mediated activation of mitogen-activated protein kinase signaling pathways in response to growth inhibition by a novel K vitamin.
Wang Z; Wang M; Carr BI
J Cell Physiol; 2000 Jun; 183(3):338-46. PubMed ID: 10797308
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell growth inhibition and extracellular signal-regulated kinase (ERK) phosphorylation by novel K vitamins.
Osada S; Osada K; Carr BI
J Mol Biol; 2001 Dec; 314(4):765-72. PubMed ID: 11733995
[TBL] [Abstract][Full Text] [Related]
4. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue.
Tamura K; Southwick EC; Kerns J; Rosi K; Carr BI; Wilcox C; Lazo JS
Cancer Res; 2000 Mar; 60(5):1317-25. PubMed ID: 10728693
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rat liver regeneration after partial hepatectomy and induction of ERK phosphorylation by Cpd 5, a K vitamin-based anticancer compound.
Kar S; Wang M; Rosi KS; Wilcox CS; Carr BI
Carcinogenesis; 2004 Dec; 25(12):2345-51. PubMed ID: 15319298
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Wang Z; Southwick EC; Wang M; Kar S; Rosi KS; Wilcox CS; Lazo JS; Carr BI
Cancer Res; 2001 Oct; 61(19):7211-6. PubMed ID: 11585757
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin.
Kar S; Carr BI
J Cell Physiol; 2000 Dec; 185(3):386-93. PubMed ID: 11056008
[TBL] [Abstract][Full Text] [Related]
8. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
Kar S; Wang M; Ham SW; Carr BI
Biochem Pharmacol; 2006 Nov; 72(10):1217-27. PubMed ID: 16930563
[TBL] [Abstract][Full Text] [Related]
9. EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog.
Kar S; Adachi T; Carr BI
J Cell Physiol; 2002 Mar; 190(3):356-64. PubMed ID: 11857451
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
Wang Z; Wang M; Carr BI
J Cell Physiol; 2005 Jun; 203(3):510-9. PubMed ID: 15534860
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
Wang Z; Ge L; Wang M; Carr BI
J Cell Physiol; 2006 Jul; 208(1):133-40. PubMed ID: 16596619
[TBL] [Abstract][Full Text] [Related]
12. Critical role of extracellular signal-regulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition.
Osada S; Saji S; Osada K
Cancer; 2001 Mar; 91(6):1156-65. PubMed ID: 11267961
[TBL] [Abstract][Full Text] [Related]
13. Binding and inhibition of Cdc25 phosphatases by vitamin K analogues.
Kar S; Lefterov IM; Wang M; Lazo JS; Scott CN; Wilcox CS; Carr BI
Biochemistry; 2003 Sep; 42(35):10490-7. PubMed ID: 12950176
[TBL] [Abstract][Full Text] [Related]
14. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
Ahmad N; Gali H; Javed S; Agarwal R
Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
[TBL] [Abstract][Full Text] [Related]
15. Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a vitamin K analog.
Ge L; Wang Z; Wang M; Kar S; Carr BI
J Hepatol; 2004 Nov; 41(5):823-9. PubMed ID: 15519656
[TBL] [Abstract][Full Text] [Related]
16. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.
Kar S; Wang M; Carr BI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):831-40. PubMed ID: 18246350
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
18. Antitumor and anticarcinogenic actions of Cpd 5: a new class of protein phosphatase inhibitor.
Kar S; Wang M; Wilcox CS; Carr BI
Carcinogenesis; 2003 Mar; 24(3):411-6. PubMed ID: 12663499
[TBL] [Abstract][Full Text] [Related]
19. Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells.
Mizuno R; Oya M; Hara S; Matsumoto M; Horiguchi A; Ohigashi T; Marumo K; Murai M
Oncol Rep; 2005 Sep; 14(3):639-44. PubMed ID: 16077967
[TBL] [Abstract][Full Text] [Related]
20. The protein kinase C inhibitor Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] potentiates agonist-induced mitogen-activated protein kinase activation through tyrosine phosphorylation of the epidermal growth factor receptor.
Shah BH; Olivares-Reyes JA; Catt KJ
Mol Pharmacol; 2005 Jan; 67(1):184-94. PubMed ID: 15465928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
